

## **NA-SEMAX:**

# Clinical Overview for Brain and Body Enhancement

### **NA-SEMAX**

(acetylated ACTH(4-10) analog)

Shows neuroprotective, neurotropthic, nootropic, and cardioprotective activities.



### NA-SEMAX: Clinical Overview for Brain and Body Enhancement

#### Overview

NA-SEMAX, a synthetic analog of ACTH (4-10), demonstrates significant neuroprotective, neurotrophic, nootropic, and cardioprotective activities. Chemically acetylated and amidated, NA-SEMAX penetrates the blood-brain barrier effectively, providing therapeutic benefits for cognitive, neurological, and cardiovascular health [1,2].

Pharmacodynamics and Mechanism of Action

NA-SEMAX mediates its beneficial effects through multiple mechanisms:

- Neurotransmitter Modulation:
  - o Enhances dopamine, serotonin, and acetylcholine signaling [1,3].
  - o Balances glutamate and GABA systems, reducing excitotoxicity [4].
- Neurotrophic Enhancement:
  - Stimulates synthesis and release of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), essential for neuronal survival, neurogenesis, and plasticity [2,5].
- Anti-inflammatory and Antioxidant Actions:
  - o Suppresses pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) [6].
  - o Enhances endogenous antioxidants (e.g., Superoxide Dismutase, Catalase), thereby reducing oxidative stress [7].
- Cardiovascular Benefits:
  - Protects myocardium against ischemia-reperfusion injury and improves endothelial function [8].
  - o Stabilizes autonomic regulation, potentially reducing arrhythmia risk [9].

#### **Clinical Applications and Benefits**

Neurological Improvement:

- Cognitive Function:
  - o Improves memory, attention, learning capacity, and information processing speed [1,10].
- Mood and Emotional Regulation:
  - o Reduces anxiety and depressive symptoms, enhancing emotional resilience and stress tolerance [2,11].
- Neuroprotection:
  - o Significantly beneficial post-TBI, stroke, Alzheimer's disease, Parkinson's disease, and chronic stress-induced cognitive impairment [12,13].



#### **Cardiovascular Improvement:**

- Enhances myocardial resistance to ischemic injury.
- Improves vascular endothelial function, potentially reducing atherosclerotic risk and promoting cardiovascular health [8,9].

#### **Suggested Dosing and Administration**

Typical dosages include:

- Neurocognitive enhancement: mcg intranasally per day.
- Acute neuroprotection (e.g., post-TBI): mcg/day in divided doses.
- Cardiovascular protection: mcg intranasally daily.

Administration Route: Intranasal administration ensures rapid absorption and CNS availability.

#### **Side Effects and Safety Profile**

- NA-SEMAX has an excellent safety profile with minimal adverse reactions reported in clinical practice [2,14].
- Occasional mild side effects: transient nasal irritation, headache, mild insomnia (usually dosedependent).

#### **Contraindications and Precautions**

- Pregnancy/Breastfeeding: Limited safety data; caution or avoid usage unless explicitly necessary.
- Severe cardiovascular instability: Carefully evaluate due to potential modulation of autonomic balance.

#### **Clinical Monitoring Recommendations**

- Evaluate baseline cognitive, emotional, and cardiovascular status.
- Periodic clinical evaluations (every 4–6 weeks) to optimize dose and duration.

#### **Clinical Summary**

NA-SEMAX represents a significant therapeutic advance with broad-spectrum applicability for enhancing neurological and cardiovascular health. Healthcare providers can leverage its multifaceted benefits to optimize clinical outcomes, particularly in patients experiencing cognitive impairment, mood disorders, neurological injuries, or cardiovascular concerns.



#### References

- 1. Ashmarin, I. P., et al. (2005). Semax: From molecular mechanisms to clinical effects. *Neuroscience and Behavioral Physiology*, 35(6), 605-618.
- 2. Kolomin, T., et al. (2013). Semax, an ACTH(4-10) analogue with neuroprotective activity, regulates gene expression involved in cell proliferation and differentiation. *Neurochemical Journal*, 7(4), 295-304.
- 3. Levitskaya, N. G., et al. (2004). Effects of Semax on dopamine turnover in striatum of rats. *Bulletin of Experimental Biology and Medicine*, 137(6), 600-602.
- 4. Filippenkov, I. B., et al. (2019). Transcriptomic responses to Semax peptide administration in ischemic rat brain. *Molecular Neurobiology*, 56(8), 5479-5489.
- 5. Shadrina, M., et al. (2010). Expression of genes associated with inflammation and neurogenesis in rat brain after treatment with Semax. *Journal of Molecular Neuroscience*, 41(1), 30-34.
- 6. Umriukhin, A. E., et al. (2007). Anti-inflammatory activity of Semax in the early stages of brain ischemia. *Bulletin of Experimental Biology and Medicine*, 144(2), 236-238.
- 7. Andreeva, L. A., et al. (2001). Effects of Semax on antioxidant defense and lipid peroxidation in brain during ischemia. *Bulletin of Experimental Biology and Medicine*, 132(4), 878-880.
- 8. Dergunova, L. V., et al. (2019). Cardioprotective properties of Semax peptide under myocardial ischemia and reperfusion. *Doklady Biochemistry and Biophysics*, 485(1), 98-101.
- 9. Azevedo, L. C., et al. (2017). Cardiac autonomic modulation and arrhythmias: Role of oxidative stress and inflammation. *Oxidative Medicine and Cellular Longevity*, 2017, Article ID 7953091.
- 10. Yatsenko, K. A., et al. (2015). Influence of Semax on memory formation processes. *Journal of Evolutionary Biochemistry and Physiology*, 51(2), 105-114.
- 11. Volkov, A., et al. (2014). Semax peptide modulates cognitive functions and improves emotional state in chronic stress conditions. *International Journal of Peptide Research and Therapeutics*, 20(1), 53-61.
- 12. Eremin, K. O., et al. (2020). Neuroprotective effects of Semax following traumatic brain injury. *Brain Research Bulletin*, 160, 19-28.
- 13. Sokolov, A. Y., et al. (2020). Semax reduces neurodegeneration in Alzheimer's disease animal models by enhancing synaptic plasticity. *Frontiers in Neuroscience*, 14, 275.
- 14. Guseva, D., et al. (2008). Intranasal administration of Semax, an ACTH(4-10) analog, as a nootropic agent. *Peptides*, 29(3), 351-357.